Trevi Therapeutics

Trevi Therapeutics announces senior management participation in October and November conferences: 3rd Chief Commercial Officer Summit (Oct 23-24, Philadelphia), BIO-Europe (Nov 4-6, Stockholm), and Stifel 2024 Healthcare Conference (Nov 18-19, New York).

Starting a biotech company involves navigating scientific validation, regulatory requirements, and fundraising challenges. Founders must choose the right focus, leverage university collaborations, attract investments, and build a strong team. Regulatory and IP strategies are crucial, and founders should be prepared for a long, challenging journey.

Trevi Therapeutics announced milestones in its clinical trials, including the Phase 2b CORAL trial reaching 50% enrollment for chronic cough in idiopathic pulmonary fibrosis patients, with top-line results expected in H1 2025. The Human Abuse Potential study completed dosing, and the Phase 2a RIVER trial for refractory chronic cough met its sample size, with results anticipated in Q1 2025. Analysts have initiated coverage with positive ratings, despite a net loss of $12.4 million in Q2 2024. Trevi's financial stability is supported by its cash reserves.

Trevi Therapeutics reports 50% enrollment in Phase 2b CORAL trial for IPF chronic cough, with SSRE results expected in December 2024. HAP study dosing complete, with topline results also expected in December 2024. Phase 2a RIVER trial for RCC enrollment complete, with topline results expected in Q1 2025.

Trevi Therapeutics appoints James V. Cassella, Ph.D., as Chief Development Officer to lead Haduvio™ development for chronic cough in IPF and RCC, leveraging his extensive CNS drug development experience.